Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort
Sign Up to like & getrecommendations! Published in 2017 at "Oncogene"
DOI: 10.1038/onc.2016.283
Abstract: Amplification of the MET oncogene occurs in 2–4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have… read more here.
Keywords: met egfr; egfr therapy; resistance; dual met ... See more keywords
Abstract PO1-25-03: Programmed Death-Ligand 1 and Receptor Tyrosine Kinases in Breast Cancer
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po1-25-03
Abstract: Programmed death-ligand 1 (PD-L1) is an immune checkpoint expressed in a wide range of malignancies leading to immune tolerance and cancer cell immune evasion. Receptor tyrosine kinases (RTKs) are key regulators of cancer cell proliferation,… read more here.
Keywords: receptor; cancer; breast cancer; met egfr ... See more keywords
Erratum to combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?
Sign Up to like & getrecommendations! Published in 2017 at "Translational lung cancer research"
DOI: 10.21037/tlcr.2017.08.07
Abstract: [This corrects the article DOI: 10.21037/tlcr.2017.04.06.]. read more here.
Keywords: directed therapy; egfr directed; erratum combination; met egfr ... See more keywords